Diabetic Retinopathy Market : Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024

Date : Mar 2018

Formats :
Report Code : PMR83649614

Category : Pharmaceutical and Healthcare
No Of Pages :
Report Snapshot of Diabetic Retinopathy Market: Diabetic retinopathy is the most common form of diabetic eye disease. Diabetic retinopathy usually affects the people with diabetes from number of years. High glucose levels in the cause damage to the retinal blood vessels is the main manifestation in diabetic retinopathy. In some other cases, the retinal blood vessels will be swollen macular oedema with a fluid leaking into rear of eye. In few cases, on the surface of the retinal blood vessels will grow abnormally. If diabetic retinopathy is not properly treated, can progressively become more serious and seriously affects vision which may leads to blindness.

Global Market Outline: Diabetic Retinopathy Market

Diabetic Retinopathy will affect both type 1 and type 2 diabetic patients and due to the abundant increase in the pool of patients with Diabetes, According to the World Health Organisation WHO, 41 % of global population with diabetes are geriatric patients which is highly attributing the growth of the diabetic retinopathy market. Furthermore, rise in healthcare infrastructure upgradation, rise in demand for the early diagnosis devices are the few factors having significant impact in driving the diabetic retinopathy market. However, paucity of skilled ophthalmologist, lack of primary infrastructure and insurance facilities are some of the restraining factors that are hampering the growth of diabetic retinopathy market.

The global diabetic retinopathy treatment market is segmented on the basis of treatment, end users, type, and geographical regions.

Based on the type, global diabetic retinopathy treatment market is segmented as:
Proliferative Diabetic Retinopathy
Diabetic Macular Edema

Based on the drug class, the global diabetic retinopathy treatment market is segmented as:
Corticosteroids
AntiVEGF vascular endothelial growth factor

Based on the basis distribution channels, the global Diabetic retinopathy Treatment Market is segmented as:
Ophthalmic Clinics
Hospital Pharmacies
Retail pharmacies

Diabetic retinopathy can be treated by various methods depending on the stage of disease. Diabetic retinopathy is one of the major causes of blindness in adult population in America. As per, World Health Organisation WHO, 347 Mn people were suffering from diabetes globally in 2013, in which 11% population are having diabetic retinopathy. Increase in focus on Asiapacific and LAMEA regions by various vendors is expected to boost growth of the market According to the World Bank, in 2015,10.4% of rate of prevalence of diabetes was observed in Brazil. Strategic acquisitions, geographic expansion, agreements, partnerships and new product launches are the most vital strategic implementations by most of the companies in the market of diabetic retinopathy.

On the basis of regions, the global market of diabetic retinopathy has been segmented into five key regions, Latin America North America, AsiaPacific, Europe, and Middle East & Africa. North America dominates the market followed by AsiaPacific and Europe. The factors that are attributing for the market growth in North America are, people with high obesity rates are more prone to diabetes conditions. Large patient pool in European region with diabetic retinopathy is expected to drive the growth of the market. In emerging economies, due to the improvement in the healthcare infrastructure and rise in awareness in the people Owing to improved infrastructure and awareness among the people, improving on the quality of life QALY in diabetic patients, rise in demand of early detection and treatment of chronic conditions such as diabetic retinopathy are the factors that are driving the growth of the diabetic retinopathy market in Asia Pacific regions.

Some of the players in diabetic retinopathy market are Abbott Laboratories U.S., Alimera Sciences U.S., Allergan plc Ireland., Ampio Pharmaceuticals. U.S., Bayer AG Germany, F. HoffmannLa Roche Switzerland, Novartis AG Switzerland, Pfizer Inc. U.S., Regeneron Pharmaceuticals Inc. U.S., and Valeant Canada

In 2018, Roche got FDA approval for Lucentis Ranibizumab injection for the treatment of diabetic retinopathy

In 2014, Regeneron Pharmaceuticals, EYLEA® aflibercept injection received USFDA breakthrough therapy designation for to treat diabetic retinopathy in patients with diabetic macular edema DME

In 2014, Regeneron Pharmaceuticals, EYLEA® aflibercept injection received European Commission to treat diabetic retinopathy in patients with diabetic macular edema DME
1. Executive Summary
2. Global Diabetic Retinopathy Market Introduction
2.1. Global Diabetic Retinopathy Market – Taxonomy
2.2. Global Diabetic Retinopathy Market –Definitions
2.2.1. Diabetic Retinopathy Type
2.2.2. Distribution Channel
3. Global Diabetic Retinopathy Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Diabetic Retinopathy Market Dynamic Factors Impact Analysis
4. Global Diabetic Retinopathy Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
4.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
4.2. YearoverYear YoY Growth Analysis %
4.3. Market Opportunity Analysis
5. Global Diabetic Retinopathy Market, By Diabetic Retinopathy Type, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.1. Proliferative Diabetic Retinopathy
5.1.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.1.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.1.3. Market Opportunity Analysis
5.2. Diabetic Macular Edema
5.2.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.2.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.2.3. Market Opportunity Analysis
6. Global Diabetic Retinopathy Market, By Drug Class, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
6.1. Corticosteroids
6.1.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
6.1.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
6.1.3. Market Opportunity Analysis
6.2. AntiVEGF Vascular Endothelial Growth Factor
6.2.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
6.2.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
6.2.3. Market Opportunity Analysis
7. Global Diabetic Retinopathy Market, By Distribution Channel, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.1. Ophthalmic Clinics
7.1.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.1.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.1.3. Market Opportunity Analysis
7.2. Hospital Pharmacies
7.2.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.2.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.2.3. Market Opportunity Analysis
7.3. Retail Pharmacies
7.3.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.3.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.3.3. Market Opportunity Analysis
7.4. Online Pharmacies
7.4.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.4.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.4.3. Market Opportunity Analysis
8. Global Diabetic Retinopathy Market Forecast, By Region, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
8.1. North America
8.1.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
8.1.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
8.2.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
8.2.3. Market Opportunity Analysis
8.3. AsiaPacific
8.3.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
8.3.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
8.4.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
8.5.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
8.5.3. Market Opportunity Analysis
8.6. Global Diabetic Retinopathy Market Opportunity Analysis Index, By Diabetic Retinopathy Type, By Drug Class, By Distribution Channel, and Region, 2018 – 2024
9. North America Diabetic Retinopathy Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
9.1. Diabetic Retinopathy Type Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
9.1.1. Proliferative Diabetic Retinopathy
9.1.2. Diabetic Macular Edema
9.2. Drug Class Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
9.2.1. Corticosteroids
9.2.2. AntiVEGF Vascular Endothelial Growth Factor
9.3. Distribution Channel Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
9.3.1. Ophthalmic Clinics
9.3.2. Hospital Pharmacies
9.3.3. Retail pharmacies
9.3.4. Online Pharmacies
9.4. Country Analysis 2017 and Forecast 2018 – 2024 by Revenue USD Mn YoY Growth % and Market Share %
9.4.1. U.S.
9.4.2. Canada
9.5. North America Diabetic Retinopathy Market Opportunity Analysis Index, By Diabetic Retinopathy Type, By Drug Class, By Distribution Channel, and Country, 2018 – 2024
9.6. North America Diabetic Retinopathy Market Dynamics – Trends
10. Europe Diabetic Retinopathy Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
10.1. Diabetic Retinopathy Type Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
10.1.1. Proliferative Diabetic Retinopathy
10.1.2. Diabetic Macular Edema
10.2. Drug Class Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
10.2.1. Corticosteroids
10.2.2. AntiVEGF Vascular Endothelial Growth Factor
10.3. Distribution Channel Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
10.3.1. Ophthalmic Clinics
10.3.2. Hospital Pharmacies
10.3.3. Retail pharmacies
10.3.4. Online Pharmacies
10.4. Country Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn YoY Growth % and Market Share %
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Diabetic Retinopathy Market Opportunity Analysis Index, By Diabetic Retinopathy Type, By Drug Class, By Distribution Channel, and Country, 2018 – 2024
10.6. Europe Diabetic Retinopathy Market Dynamics – Trends
11. AsiaPacific Diabetic Retinopathy Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
11.1. Diabetic Retinopathy Type Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
11.1.1. Proliferative Diabetic Retinopathy
11.1.2. Diabetic Macular Edema
11.2. Drug Class Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
11.2.1. Corticosteroids
11.2.2. AntiVEGF Vascular Endothelial Growth Factor
11.3. Distribution Channel Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
11.3.1. Ophthalmic Clinics
11.3.2. Hospital Pharmacies
11.3.3. Retail pharmacies
11.3.4. Online Pharmacies
11.4. Country Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn YoY Growth % and Market Share %
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of AsiaPacific
11.5. AsiaPacific Diabetic Retinopathy Market Opportunity Analysis Index, By Diabetic Retinopathy Type, By Drug Class, By Distribution Channel, and Country, 2018 – 2024
11.6. AsiaPacific Diabetic Retinopathy Market Dynamics – Trends
12. Latin America Diabetic Retinopathy Market Analysis, 2013 2013 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
12.1. Diabetic Retinopathy Type Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
12.1.1. Proliferative Diabetic Retinopathy
12.1.2. Diabetic Macular Edema
12.2. Drug Class Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
12.2.1. Corticosteroids
12.2.2. AntiVEGF Vascular Endothelial Growth Factor
12.3. Distribution Channel Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
12.3.1. Ophthalmic Clinics
12.3.2. Hospital Pharmacies
12.3.3. Retail pharmacies
12.3.4. Online Pharmacies
12.4. Country Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn YoY Growth % and Market Share %
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Diabetic Retinopathy Market Opportunity Analysis Index, By Diabetic Retinopathy Type, By Drug Class, By Distribution Channel, and Country, 2018 – 2024
12.6. Latin America Diabetic Retinopathy Market Dynamics – Trends
13. Middle East and Africa Diabetic Retinopathy Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
13.1. Diabetic Retinopathy Type Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
13.1.1. Proliferative Diabetic Retinopathy
13.1.2. Diabetic Macular Edema
13.2. Drug Class Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
13.2.1. Corticosteroids
13.2.2. AntiVEGF Vascular Endothelial Growth Factor
13.3. Distribution Channel Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
13.3.1. Ophthalmic Clinics
13.3.2. Hospital Pharmacies
13.3.3. Retail pharmacies
13.3.4. Online Pharmacies
13.4. Country Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn YoY Growth % and Market Share %
13.4.1. Gulf Cooperation Council GCC Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Diabetic Retinopathy Market Opportunity Analysis Index, By Diabetic Retinopathy Type, By Drug Class, By Distribution Channel, and Country, 2018 – 2024
13.6. MEA Diabetic Retinopathy Market Dynamics – Trends
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis
14.2.1. Abbott Laboratories U.S.
14.2.2. Alimera Sciences U.S.
14.2.3. Allergan plc Ireland.
14.2.4. Ampio Pharmaceuticals. U.S.
14.2.5. Bayer AG Germany
14.2.6. F. HoffmannLa Roche Switzerland
14.2.7. Novartis AG Switzerland
14.2.8. Pfizer Inc. U.S.
14.2.9. Regeneron Pharmaceuticals Inc. U.S.
14.2.10. Valeant Canada
15. Research Methodology
16. Key Assumptions and Acronyms
  Purchase Options for Report

Need More information

Call us :
USA : +1 7162260907
UK : +44 7441952057
....
sales@planetmarketreports.com

Why to choose PMR

PMR Market Research

Our syndicated research reports cover 50+ industry sectors offering you product and country wise breakup of the market along with niche data and insights that will help you make informed business decision. Our research is focused on the key segments of an industry that possess opportunities of growth.

  • Industrial ...
  • Business ....
  • Consumer ....
  • Peer ....

About Report

Planet Market Reports added Latest and detailed market study report that focuses on “Diabetic Retinopathy Market" Which offers essential information based on fresh ideas into Diabetic Retinopathy Market industry along with unique market analysis which covers current top Manufactures in Diabetic Retinopathy Market, growth, Consumption Demand, challenges, Historical data, subjects wise Survey of each chapters, Regional Insights, and Advancing industry trends, which will help our clients to aim Diabetic Retinopathy Market. In addition, the report helps the customers to get a brief idea about Future demand and specifications of products which ensures the driving long-term income and productivity of global market.